White Matter Changes in Patients with Friedreich Ataxia after Treatment with Erythropoietin

K. Egger, C. Clemm von Hohenberg, M. F. Schocke, C. R. G. Guttmann, D. Wassermann, M. C. Wigand, W. Nachbauer, C. Kremser, B. Sturm, B. Scheiber-Mojdehkar, M. Kubicki, M. E. Shenton, S. Boesch
J NEUROIMAGING
2013

Download full paper

Abstract

Erythropoietin (EPO) has received growing attention because of its neuroregenerative properties. Preclinical and clinical evidence supports its therapeutic potential in brain conditions like stroke, multiple sclerosis, and schizophrenia. Also, in Friedreich ataxia, clinical improvement after EPO therapy was shown. The aim of this study was to assess possible therapy-associated brain white matter changes in these patients.

Reference

Egger K, von Hohenberg CC, Schocke MF, Guttmann CRG, Wassermann D, Wigand MC, Nachbauer W, Kremser C, Sturm B, Scheiber-Mojdehkar B, Kubicki M, Shenton ME, Boesch S. White matter changes in patients with friedreich ataxia after treatment with erythropoietin. J NEUROIMAGING 2013;.

Research area

dti
© 2013 Psychiatry Neuroimaging Laboratory | Last updated 04.15.2013